Normalization of mutant transcript to the wild-type transcript.

Current guidelines recommend that Acute Myeloid Leukemia (AML) patients with mutations should be monitored for measurable residual disease by quantifying the transcripts and normalizing them to transcripts. In this short report, a simple and highly accurate method to quantify the mutant transcript normalized to the wild-type transcript is presented. The percent mutant transcript correlates very well to the corresponding mutant allele frequency as determined by DNA-based methods allowing direct comparison of investigational studies that use RNA-based or DNA-based methods for monitoring mutations.